Pergoveris in controlled ovarian stimulation in assisted reproductive technology programms


  • В. В. Веселовский Clinic of Reproductive Medicine «Nadia», Kiev, Ukraine



assisted reproductive technologies, controlled ovarian stimulation, Pergoveris


It was performed a study to examine the use of Pergoveris in the controlled ovarian stimulation (COS) in assisted reproductive technology (ART). The results showed that the addition of luteinizing hormone (especially recombinant) into COS protocols do not provide the benefits in patients with normal ovarian reserve, and under the age of 37 years. There was a significant decrease in the number of oocytes obtained after using drugs containing luteinizing hormone, so it should not use urinary gonadotropins during ART cycles in which pre-implantation genetic diagnosis is carry out. Pergoveris showed promising results during the COS in women older than 37 years, especially older than 40 years.

Author Biography

В. В. Веселовский, Clinic of Reproductive Medicine «Nadia», Kiev

Medical director


  1. Acevedo B, Sanchez M, Gomez JL et al. Luteinizing hormone supplementation increases pregnancy rates in gonadotropin releasing hormone antagonist donor cycles. Fertility and Sterility 2004, 82, 343–347.
  2. Andersen AN, Devroey P, Arce JC Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod. 2006; 21(12): 3217–3227.
  3. Barrenetxea G,Agirregoikoa JA, Jimenez MR, de Larruzea AL, Ganzabal T, Carbonero K Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertil Steril. 2008; 89(3): 546–553.
  4. Berger MJ, Taymor ML The role of luteinizing hormone in human follicular maturation and function. Am J Obstet Gynecol. 1971 Nov 1; 111(5): 708–10.
  5. Bosch E Recombinant human FSH and recombinant human LH in a 2:1 ratio combination: a new tool for ovulation induction. Expert Rev. Obstet. Gynecol. 2009 4, 491–498.
  6. Bosch E, Labarta E, Crespo J, Simon C, Remohi J, Pellicer A Impact of luteinizing hormone administration gongonadotropin-releasing hormone antagonist cycles: anage-adjusted analysis. Fertil. Steril. 2011 95, 1031–1036.
  7. Buehler K, Naether O A 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice: a large, multicentre, observational study. Gynecological Endocrinology, 2010; 1–5.
  8. De Placido G, Alviggi C, Mollo A, Strina I, Varricchio MT, Molis M Recombinant follicle stimulating hormone is effective in poor responders to highly purified follicle stimulating hormone. Hum Reprod. 2000; 15(1): 17–20.
  9. De Placido G, Alviggi C, MolloA et al. Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary down-regulation. Clinical Endocrinology 200460, 637–643.
  10. De Placido G, Alviggi C, Perino A et al. On behalf of the Italian Collaborative Group on Recombinant Human Luteinizing Hormone. Recombinant human LH supplementation versus recombinant human FSH (rhFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial
  11. inadequate ovarian response to rhFSH. A multicentre, prospective, randomized controlled trial. Human Reproduction 2005, 20, 390–396.
  12. De Placido G, Mollo A, Clarizia R et al. Gonadotropin-releasinghormone (GnRH) antagonist plus recombinant luteinizing hormonevs. A standard GnRH agonist short protocol in patients at risk forpoor ovarian response. Fertility and Sterility 2006 85, 247–250.
  13. Fabregues F, Creus M, Penarrubia J, Manau D, Vanrell JA, Balasch J Effect of recombinant human luteinizing hormone supplementation on ovarianstimulation and the implantation rate in down-regulated women of advanced reproductive age. Fertil Steril 2006; 85: 925–931.
  14. Fábregues F, Creus M, Casals G, Carmona F, Balasch J Outcome from consecutive ICSI cycles in patients treated with recombinant human LH and those supplemented with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol. Gynecol Endocrinol. 2013 May; 29(5): 430-5.
  15. Ferraretti AP, Gianaroli L, Magli MC et al. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril. 2004 82, 1521–1526.
  16. Filicori M,Cognigni GE, Taraborrelli S et al. Luteinizing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. Journal of Clinical Endocrinology and Metabolism 2001 87, 1156–1161.
  17. Franco JG, Baruffi RLR, Oliveira JBA, Mauri AL, Petersen CG, Contart P, Felipe V Effects of recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-agonist protocol: a matched case-control study. Reproductive Biology and Endocrinology 2009, 7: 58.
  18. Hillier SG Current concepts of the roles of FSH and LH in folliculogenesis Hum Rep (1994) 9 188–191.
  19. Humaidan P, Bungum L, Bungum M et al. Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down regulation and recombinant FSH stimulation. Human Reproduction2002 17, 2016–2021.
  20. Humaidan P, Bungum M, Andersen YC Effects of recombinantLH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reproductive Bio Medicine Online 2004 8, 635–643.
  21. Lahoud R, Al-Jefout M, Tyler J et al. A relative reduction in midfollicular LH concentrations during GnRH agonist IVF/ICSI cycles leads to lower live birth rates Hum Rep, 2006 21, 2645–2649.
  22. Lisi F, Rinaldi L, Fishel S et al. Use of recombinant LH in a group of unselected IVF patients. Reprod Bio Medicine Online 2002 5,104–108.
  23. Lisi F, Rinaldi L, Fishel S, Lisi R, Pepe G, Picconeri M.G Use of recombinant follicle-stimulating hormone (Gonal F)and recombinant luteinizing hormone (Luveris) for multiplefollicular stimulation in patients with a suboptimal response toin vitro fertilization. Fertil. Steril. 2003 79, 1037–1038.
  24. Marrs R, Meldrum D, Muasher S et al. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reproductive Bio Medicine Online2004 8, 175–182.
  25. Matorras R, Prieto B, Exposito A, Mendoza R, Crisol L, Herranz P, Burgue´s S 2009. Mid-follicular LH supplementation in women aged 35–39 years undergoing ICSI cycles: a randomized controlled study. Reprod. Biomed. Online 19, 879–987.
  26. Mochtar MH, Vander Veen, Ziech M, van Wely M Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews 2007, CD005070.
  27. Nakagawa K, Ohgi S, Nakashima A, Horikawa T, Sugiyama R, Saito H The ratio of late-follicular to mid-follicular phase LH concentrations efficiently predicts ART outcomes in women undergoing ART treatment with GnRH-agonist long protocol and stimulation with recombinant FSH. J. Assist. Reprod. Genet. 2008 25, 359–364.
  28. Nazzaro A, Salerno A Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-antagonist protocol improves implantation and pregnancy rates. Fertility and Sterility 2012 98 Suppl., S280.
  29. O’Dea L, O’Brien F, Currie K, Hemsey G Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect. Curr Med Res Opin. 2008; 24(10): 2785–2793.
  30. Oliveira JB, Mauri AL, Petersen CG et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulation hormone during induced ovarian stimulation in the GnRH-agonist protocol: a meta-analysis. J Assist Reprod Genet. 2007; 24(2–3): 67–75.
  31. Pacchiarotti A, Sbracia M, Frega A, Selman H, Rinaldi L, Pacchiarotti A Urinary hMG (Menopur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil Steril, 2010 94(6): 2467–9.
  32. Pezzuto A, Ferrari B, Coppola F, Nardelli GB LH supplementation in down-regulated women undergoing assisted reproduction with baseline low serum LH levels. Gynecol. Endocrinol. 2010 26, 118–124.
  33. Ryan KJ, PetroZ Steroid biosynthesis by human ovarian granulosa and thecal cells. J Clin Endocrinol Metab. 1966 Jan; 26(1): 46–52.
  34. Rongieres C, Poirier V, Celebi C, Pirrello O, Bettahar K, Lehert P Adding luteinizing hormone to follicle stimulating hormone during ovarian stimulation increases pregnancy rate in IVF for poor ovarian responders. Fertility and Sterility 2012 98, Suppl., S78.
  35. Shoham Z The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertil Steril 2002 77: 1170–1177.
  36. The European Recombinant Human LH Study Group (1998) Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J. Clin. Endocrinol. Metab., 1998 May; 83(5), 1507–1514
  37. Trounson AO et al. Pregnancies in humans by fertilization in vitro and embryo transfer in the controlled ovulatory cycle. Science 212, 681–682 (1981).
  38. Van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, Al-Inany HGRecombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews 2011, Issue 2. Art. No.: CD005354.
  39. Velilla E, Fernandez S, Sunol J, Alvarez JG, Lopez-Teijon MO varian stimulation with recombinant FSH-LH results in a high recovery of euploid oocytes. Fertility and Sterility 2011 96, Suppl., S236.



How to Cite

Веселовский, В. В. (2013). Pergoveris in controlled ovarian stimulation in assisted reproductive technology programms. REPRODUCTIVE ENDOCRINOLOGY, (13), 56–60.